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Aims Supernatants of serum-free cultured mononuclear cells (MNC) contain a mix of immunomodulating factors (secre-
tome), which have been shown to attenuate detrimental inflammatory responses following myocardial ischaemia. In-
flammatory dilated cardiomyopathy (iDCM) is a common cause of heart failure in young patients. Experimental
autoimmune myocarditis (EAM) is a CD4+ T cell-dependent model, which mirrors important pathogenic aspects
of iDCM. The aim of this study was to determine the influence of MNC secretome on myocardial inflammation
in the EAM model.
Methods
and results
BALB/c mice were immunized twice with an alpha myosin heavy chain peptide together with Complete Freund ad-
juvant. Supernatants from mouse mononuclear cells were collected, dialysed, and injected i.p. at Day 0, Day 7, or Day
14, respectively. Myocarditis severity, T cell responses, and autoantibody formation were assessed at Day 21. The
impact of MNC secretome on CD4+ T cell function and viability was evaluated using in vitro proliferation and
cell viability assays. A single high-dose application of MNC secretome, injected at Day 14 after the first immunization,
effectively attenuated myocardial inflammation. Mechanistically, MNC secretome induced caspase-8-dependent apop-
tosis in autoreactive CD4+ T cells.
Conclusion MNC secretome abrogated myocardial inflammation in a CD4+ T cell-dependent animal model of autoimmune
myocarditis. This anti-inflammatory effect of MNC secretome suggests a novel and simple potential treatment
concept for inflammatory heart diseases.
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Introduction
Myocarditis denotes inflammation of the heart muscle. Clinical pre-
sentations include subclinical disease to fatal courses with
progressive heart failure, arrhythmia, and sudden death.1,2 The
cause of myocarditis often remains unknown in the individual
patient, but virus-triggered autoimmunity is thought to play an im-
portant role in disease development. Immunosuppressive regimens
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have failed to improve functional outcomes in large clinical trials of
acute myocarditis,3– 5 but are beneficial during chronic phases of
disease in patients without evidence of viral genomes in heart
muscle biopsies.6
The idea of using conditioned medium as a therapeutic agent
evolved in the field of stem cell research. Many of the regenerative
effects seen after administration of stem cells were rather
mediated via paracrine signalling than by direct cellular interac-
tions.7 Conditioned culture medium containing the secretome of
mesenchymal stem cells is rich in angiogenic and chemotactic
factors.8 Besides, there is growing evidence that stem cell condi-
tioned medium has immunomodulating features as well.9,10
We have recently shown that a high-dose application of the
secretome of peripheral blood mononuclear cells (PBMC) directly
influences the endogenous inflammatory response after acute
myocardial infarction (AMI). In a porcine closed-chest reperfusion
infarction model, an i.v. injection of PBMC secretome effectively
suppressed inflammatory responses and tissue damage.11 –13
Moreover, we were able to show that PBMC secretome also
attenuates microvascular obstruction, inhibits platelet aggregation,
and causes vasodilation in a NOS-dependent manner.14 On the
basis of these observations, we specifically addressed immunomo-
dulatory features of MNC secretome and tested its anti-
inflammatory effects in a model of autoimmune myocarditis.
Experimental autoimmune myocarditis (EAM) can be induced in
susceptible mouse strains by immunization with a heart muscle
myosin-specific peptide (MyHC-a614 – 629) together with a strong
adjuvant. The majority of immunized mice develops myocarditis
peaking 21 days after the first immunization.15 Experimental auto-
immune myocarditis represents a CD4+ cell-mediated
disease,16,17 accordingly, depletion of CD4+ cells effectively pre-
vents disease development.18–20
Here, we provide for the first time evidence that high-dose applica-
tion of MNC secretome attenuates EAM. Mechanistically, the secre-
tome induces apoptosis of autoreactive CD4+ T cells.
Methods
Generation of murine and human
mononuclear cell secretome
Spleens from donor Balb/c mice were removed and homogenized
under sterile conditions. Splenocytes were resuspended in UltraCul-
ture serum-free medium (Cambrex Corp., North Brunswick, NJ,
USA; 1 × 106 cells/mL). After incubation for 24 h supernatants were
dialysed against ammonium acetate (at a concentration of 50 mM,
cut-off 3.5kD), sterile filtered, frozen, lyophilized, and kept frozen at
2808C until further used. Mononuclear cell secretome pooled from
10 different donor mice were used for further experiments. For
some experiments, PBMC obtained from young healthy volunteers
(ethics committee vote: 2010/034) were used for the production of
MNC secretome. The mononuclear cell fraction was separated from
venous whole-blood samples by Ficoll density-gradient centrifugation.
Mononuclear cell secretome was produced according to the protocol
described above. The content of mouse and human MNC secretome
(obtained from 25 × 106 cells) was analysed using commercially avail-
able cytokine arrays (Proteome Profiler Arrays obtained from R&D,
MN, USA) following the manufacturer’s instructions.
Experimental autoimmune myocarditis
induction
Animal experiments were approved by the University of Vienna,
Austria (GZ66.009/0055-II/10b/2010). Experimental autoimmune
myocarditis was induced in 6–8-week-old Balb/c mice by subcutane-
ous injection of 150 mg of the MyHC-a (MyHC-a614 –629:
Ac-SLKLMATLFSTYASAD) or ovalbumin emulsified 1:1 in PBS/CFA
(1 mg/mL, H37Ra) with a 7-day interval between injections (on Day
0 and Day 7, respectively).21 Supernatant of 4 × 106 syngeneic,
murine MNC cultures was i.p. injected at different time points
(Day 0, Day 7, and Day 14). Injections of lyophilized culture
medium served as a negative control. Mice were sacrificed on Day
21 (climax of inflammation) and hearts were evaluated for myocardial
infiltrates.
Histopathological evaluation
Haematoxylin-eosin stained heart sections were scored according to a
semi-quantitative scale (0, indicated no inflammatory infiltrates; 1, small
foci of inflammatory cells between myocytes; 2, larger foci of .100
inflammatory cells; 3, ,10% of a cross-section involved; 4, .30% of
a cross-section involved), as previously described.22
Enzyme-linked immunosorbent assays
To characterize the impact of MNC secretome on the systemic inflam-
matory state, enzyme-linked immunosorbent assays (ELISA) were per-
formed. IL-1b, IL-6, TNF-a, IFN-g, IL-10, IL-17 and TGF-b1 were
analysed in plasma samples obtained on Day 21 using commercially
available kits (R&D, MN, USA). Formation of MyHC-a specific anti-
bodies was determined by a solid phase ELISA, coating plates with
5 mg/mL MyHC-a. Since the original peptide sequence is hydrophobic,
four lysine residues were added to the N-terminus to make the
peptide water soluble (KKKKRSLKLMATLFSTYASADR). Plasma was
diluted 1:10 for IgM, 1:50 for IgG1, 1:10 for IgG2a and IgG2b, and
1:50 for IgG3 and bound antibodies were detected with monoclonal
rat anti-mouse IgM, IgG1, IgG2a, IgG2b, and IgG3 antibodies (Pharmin-
gen, CA, USA) diluted 1:1000 and a HRP-coupled goat anti-rat anti-
serum (Amersham, Biosciences, UK) diluted 1:2000. The substrate
for HRP was ABTS [60 mM/L citric acid, 77 mM/L Na2HPO4 ×
2H2O, 1.7 mM/L ABTS (Sigma, MO, USA), 3 mM/L H2O2]. The
content of sFAS, sFASL, sCD40, and sCD40L in MNC preparations
was measured by commercially available ELISA kits (R&D Systems,
Minneapolis, MN, USA).
Flow cytometry
Isolated mouse splenocytes and human PBMC were analysed for
amounts of CD4+ T cells, CD8+ T cells, B cells, and monocytes.
Mouse spleens were dissected and passed through a 40 mm cell strain-
er (BD Biosciences). Cells were washed with PBS and remaining ery-
throcytes were lysed with a commercially available haemolysis buffer
(Morphisto, Frankfurt am Main, Germany). Isolated splenocytes and
human PBMC were washed and analysed using the following
fluorescence-labelled monoclonal antibodies: fluorescein isothiocyan-
ate (FITC)-anti-CD4, phycoerythrin (PE)-anti-CD8 and PE-anti-CD19.
All antibodies were obtained from Biozyme (Oldendorf, Germany). Ap-
propriate isotype controls were included and gates were set according
to isotype-matched controls. The content of monocytes was deter-
mined by placing a gate in the forward/side scatter dot blot. Analysis
was performed on a FACSCalibur flow cytometer (BD Biosciences),
and data were evaluated using the FlowJo software (Tree Star,
Ashland, OR, USA). To test the CD4+/CD8+ cell ration in vivo, whole-
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blood samples were obtained from mice sacrificed 12 and 36 h after
MNC secretome or medium control treatment on Day 14. Erythro-
cytes were lysed and cell pellets were stained with anti-CD4,
anti-CD8 (both Acris, Herford, Germany) and 7-Aminoactinomycin
D (7-AAD; Beckman Coulter, CA, USA). Numbers of CD4+ and
CD8+ cells, CD4+/CD8+ ratio, and amount of 7-AAD positive
CD4+ cells were determined by flow cytometry.
Proliferation assays
Spleens were homogenized and splenocytes (1 × 105) were cultured
for 5 days with different concentrations of water-soluble MyHC-a.
CD4+ cells were purified from spleens or human peripheral mono-
nuclear cells obtained from healthy volunteers using the MACS bead
system (Miltenyi Biotec, Bergisch Gladbach, Germany). 1×105 cells
per well were either stimulated with phytohaemagglutinin (PHA,
7 mg/mL, Sigma, MO, USA) or a monoclonal antibody to CD3
(10mg/mL, Becton Dickinson, NJ, USA) in 96-well round-bottom
plates. Human MNC secretome was added in different concentrations.
Plates were incubated for 5 days and then pulsed for 18 h with
3[H]-thymidine. Proliferation of splenocytes and CD4+ cells was mea-
sured in a liquid scintillation counter.
Detection of apoptosis
Purified human CD4+ T cells, JURKAT cells (ATCC, VA, USA), or
murine T cell lymphoma cells (CLS, Eppelheim, Germany) were incu-
bated in a humidified atmosphere with or without human MNC secre-
tome of 1.1 × 106 cells. Cell viability was monitored by Annexin
V-fluorescein/propidium iodide (FITC/PI) co-staining (Becton Dickin-
son, Franklin Lakes, NJ, USA) at different time points (0, 6, 12, 24 h)
or by determination of released histones (18 h) using a commercially
available kit (Roche Molecular Biochemicals, Penzberg, Germany). Al-
ternatively, purified CD4+ cells were pre-incubated for 30 min with
20 mM of different caspase inhibitors (Z-VAD, Z-DEDV, Z-IETD,
Z-LEHD; purchased from R&D, MN, USA) before adding MNC secre-
tome or lyophilized medium control. For antibody-blocking experi-
ments, CD4+ cells were pre-incubated with antibodies directed
against CD40L, FASL, VEGF, IL8, ENA78, MMP9, isotype control (all
R&D, MN, USA), TRAIL1 or TRAIL2 (both Adipogen, Liestal, Switzer-
land) for 30 min. Mononuclear cell secretome of 1.1 × 106 cells was
added and after 18 h of incubation, histone release was monitored.
Endocytosis and dendritic cell
activation assays
Blood was obtained from young healthy volunteers and monocytes
were purified by CD14 positive selection using MACS beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). Cells were incubated at concen-
tration of 1 × 106 cells/mL for 5 days with IL-4 (1000 U/mL) and
GM-CSF (50 ng/mL; both Peprotech, NJ, USA). The phenotype of
naive dendritic cells (DCs) was determined by flow cytometry using
CD14, CD1a, CD11c, CD80, CD83, CD86, and human leucocyte
antigen (HLA)-DR specific antibodies (all Beckman Coulter, CA,
USA). Endocytic activity was assessed by flow cytometry after incubat-
ing cells for 1 h with either MNC secretome (obtained from 1.25 ×
106 cells) or medium control together with 1 mg/mL FITC-Dextran
(Sigma, MO, USA). In an additional set of experiments, naive DCs
were incubated for 24 h with MNC secretome (obtained from 1.25
× 106 cells) or control medium. Then, 1 mg/mL lipopolysaccharide
(LPS; Sigma, MO, USA) was added and the expression of maturation
markers (CD80, CD83, CD86, HLA-DR) was determined by flow
cytometry.
Statistical analysis
Results are depicted as means+ standard error of the mean and levels
of significances were determined by the two-sided student’s t-test,
two-sided Mann–Whitney U test, or ANOVA adjusted by a Bonferroni
correction for multiple testings. Data analysis was performed with
SPSS 18.0 (SPSS, Inc., USA) and GraphPad Prism 5 (GraphPad Soft-
ware, Inc., CA, USA). A P-value ,0.05 was regarded as statistically sig-
nificant (*P, 0.05; **P, 0.01; ***P, 0.001).
Results
Mononuclear cell secretome attenuates
experimental autoimmune myocarditis
Mononuclear cell secretome has recently been shown to reduce
the inflammatory response during AMI. We, therefore, tested its
effects in the EAM model, which mirrors important aspects of
human inflammatory dilated cardiomyopathy (iDCM). Myosin
peptide immunized mice were treated i.p. with MNC secretome
at different time points. Secretome treatment during the phase
of immunization (Day 0 or Day 7) had no impact on the extent
of myocardial inflammation as expressed by the myocarditis
score at Day 21 (Day 0 injection: MNC secretome 2.8+0.6;
control medium: 2.3+ 0.6; P ¼ 0.606 / Day 7 injection: MNC
secretome 3.1+0.3; control medium: 3.4+0.5; P ¼ 0.639). In
contrast, injection of MNC secretome on Day 14 almost com-
pletely abrogated myocarditis at Day 21 (MNC secretome:
0.1+ 0.1; control medium: 2.4+0.4; P ¼ 0.0089; Figure 1A–D).
Hearts from MNC secretome-treated animals had only sparse
lymphocytic infiltrations and no areas of cardiomyocyte apoptosis
and/or necrosis (Figure 1E), whereas hearts from mice treated with
control medium consistently showed dense inflammatory infil-
trates (Supplementary material online, Figure S1).
Circulating levels of autoantibodies are
only marginally affected by mononuclear
cell secretome
Next, we evaluated the effect of MNC secretome on the forma-
tion of MyHC-a specific antibodies. Lower levels of circulating
IgM and IgG1 were measured in MNC-treated animals, however,
no differences in IgG2a, IgG2b, and IgG3 levels were found
between the groups (Figure 2A).
Levels of inflammatory cytokines are
reduced in mononuclear cell
secretome-treated animals
To further characterize the anti-inflammatory effect of MNC
secretome, we analysed plasma for levels of IL-1b, IL-6, TNF-a,
IFN-g, IL-10, IL-17, and TGF-b1. There were no detectable
amounts of TNF-a, IFN-g, IL-10, IL-17 in the circulation. There
was a trend of lower IL-1, IL-6, and TGF-b1 levels in the treated
group when compared with control animals, however, these
observations did not reach significance (107.9+35.5 vs. 43.7+
19.5 pg/mL; P ¼ 0.115 / 45.9+33.7 vs. 9.6+3.1 pg/mL; P ¼
0.241 / 181.4+ 103.7 vs. 12.5+0.3 pg/mL; P ¼ 0.083, respective-
ly; Figure 2B).
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Figure 1 Pathological evaluations of explanted hearts are depicted in (A–D). Mononuclear cell secretome applied during the sensitization
process (Day 0 and Day 7) had no impact on the development of myocarditis. Treating mice with mononuclear cell secretome on Day 14,
significantly reduced the lymphocytic infiltrate (mononuclear cell secretome: 0.1+0.1; control medium: 2.4+0.4; Mann–Whitney U test:
P ¼ 0.0089). A representative sample of a heart section is shown in (E). In the heart of a control mouse, treated with ‘unconditioned’
medium a dense inflammatory infiltrate was seen, whereas only scattered, infiltrating lymphocytes can be found in the animal treated with
mononuclear cell secretome.
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Figure 2 Evaluation of the autoantibody formation against MyHC-a is shown in (A). IgM and IgG1 levels were lower in mononuclear cell-
treated animals, however, other immunoglobulin subtypes remained unchanged. Cytokine analysis of plasma samples obtained during scarifica-
tion showed that the systemic inflammatory response was dampened in mice treated with mononuclear cell secretome when compared with
control animals (B). Splenocytes obtained from mice after scarification evidenced a decreased proliferatory capacity against MyHC-a in a dose-
dependent manner if animals were treated with mononuclear cell secretome (C).
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Splenocyte proliferation to MyHC-a614–629
is strongly impaired in mononuclear cell
secretome-treated animals
Previous studies have shown that proliferative responses to the
myosin peptide in vitro are strongly linked to the development of
EAM.22,23 We, therefore, isolated splenocytes from immunized
mice, treated with either MNC secretome or control medium
on Day 21. Splenocytes were stimulated with different concentra-
tions of MyHC-a and proliferation was assessed by measuring
3[H]-thymidine uptake. As shown in Figure 2C, proliferation of sple-
nocytes obtained from MNC secretome-treated animals was sig-
nificantly impaired as calculated by ANOVA (Figure 2C).
Mononuclear cell secretome obtained
from mouse splenocytes is comparable
with mononuclear cell secretome
obtained from human peripheral blood
mononuclear cells
As a proof of principle that MNC secretome produced from
mouse splenocyte cultures is comparable with MNC secretome
from human PBMC cultures, we evaluated the distribution of
CD4+ T cells, CD8+ T cells, B cells, and monocytes and per-
formed cytokine arrays with both secretomes. Although spleno-
cytes contained markedly more B cells, levels of secreted
proteins were comparable in both preparation (Supplementary
material online, Figure S2A and B, Figure 3A). Both secretomes con-
tained considerable amounts of IL-1Ra, IL-16, MCP-1, RANTES,
and sICAM-1. All other tested cytokines and chemokines were
only present in low concentrations.
Mononuclear cell secretome suppresses
proliferation of CD41 T cells in vitro but
has no impact on dendritic cell function
Experimental autoimmune myocarditis is a CD4+ T cell-mediated
disease. We, therefore, investigated the effect of MNC secretome
on CD4+ cell proliferation in vitro. First, purified human CD4+
cells were stimulated either with PHA or with a monoclonal anti-
body to the T cell receptor. The addition of MNC secretome to
the stimulation assays significantly reduced the proliferative re-
sponse in a dose-dependent manner (Figure 3B). Since MNC secre-
tome treatment on Day 0 and Day 7 had no impact on the
development of myocarditis and dendritic cells (DCs) are consid-
ered pivotal during this sensitization process, we sought to further
highlight the role of MNC secretome on DC function. Although
the maturation of monocyte-derived dendritic cells seemed to
be slightly impaired by MNC secretome treatment, endocytosis ac-
tivity was not influenced (Supplementary material online, Figure
S3A and B).
Mononuclear cell secretome induces
apoptosis in CD41 T cells, JURKAT, and
murine T cell lymphoma cells
Next, we evaluated the effect of MNC secretome on cell viability.
Co-incubation of unstimulated CD4+ T cells, a JURKAT cell line
or a mouse lymphoma cell line with MNC secretome resulted in
an apoptosis induction as determined by Annexin V/PI co-staining
and by histone release assays (Figure 3C and E, Supplementary ma-
terial online, Figure S2C ). To exclude direct cytotoxic effects of
MNC secretome, we pre-incubated cells with a pan-caspase inhibi-
tor. Induction of apoptosis was inhibited by adding Z-VAD to the
experimental setting (MNC secretome: 1.56+0.11 O.D.; MNC
secretome + Z-VAD 20 mM: 0.09+0.07 O.D.; P ¼ 0.008; MNC
secretome + Z-VAD 100 mM: 0.01+0.01 O.D.; P ¼ 0.005;
Figure 3D).
Caspase blocking experiments
To define whether apoptosis is mediated through external or
mitochondrial pathways, we selectively blocked caspase-9,
caspase-8, and caspase-3. Pre-incubation of purified CD4+ T
cells with caspase-8 and caspase-3 but not caspase-9 inhibitors
resulted in a significantly reduced Annexin staining (Figure 3F).
These observations indicate that the external pathway is involved
in MNC secretome-mediated apoptosis. Consequently, we evalu-
ated known apoptosis-inducing factors in the secretome. As illu-
strated in Figure 3G, TNF-a, sCD40L, sFASL, and sFAS were only
present in low concentrations in the MNC secretome. These find-
ings suggest that the pro-apoptotic capacity is largely mediated by
still unknown factor(s) or by a not yet understood interplay
between several specific factors within the secretome.
Blocking antibodies against known
pro-apoptotic are ineffective in reversing
CD41 T cell apoptosis
To characterize the role of known pro-apoptotic factors in the
apoptosis-inducing capacity of MNC secretome we co-incubated
purified CD4+ T cells with blocking antibodies directed against
CD40L, TRAIL1, TRAIL2, and FASL. Antibodies directed against
different chemokines without an apoptosis-inducing capacity
(VEGF, IL8, ENA78, and MMP9) served as control. Histone
release of MNC secretome-treated CD4+ cells was not
reduced by blocking these factors, indicating that MNC secretome
display its cell death inducing feature aside commonly accepted
pathways (Figure 3H).
CD4/CD8 cell ratio is reduced in
mononuclear cell secretome-treated
animals
On the basis of our in vitro findings, we measured CD4+ and
CD8+ cells 12 and 36 h after treating EAM animals with MNC
secretome or control medium. The CD4/CD8 ratio was reduced
in mice receiving the treatment when compared with control
animals although this trend reached significance only at the 36 h
timepoint (12 h: 2.1+ 0.3 vs. 1.7+0.4; P ¼ 0.441; 36 h: 2.9+
0.2 vs. 2.0+ 0.1; P ¼ 0.007; Table 1). In parallel, the number of
7-AAD positive circulating CD4+ cells was increased in MNC
secretome-treated animals when compared with the control
group.
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Figure 3 Results of cytokine arrays of mononuclear cell secretome obtained from cultured mouse splenocytes and mononuclear cell secre-
tome obtained from cultured human peripheral blood mononuclear cell are depicted in (A). Both preparations were comparable regarding their
secreted products. (B) The proliferative response of purified human CD4+ cells in the presence or absence of mononuclear cell secretome.
CD4+ cells stimulated with phytohaemagglutinin or anti-CD3 showed lower proliferation rates when treated with mononuclear cell secre-
tome. Unstimulated, purified CD4+ cells or a commercially available T cell line (JURKAT) undergo apoptosis in the presence of mononuclear
cell secretome as shown by flow cytometry (C and E) and by histone release assay (D). This effect was partially reversible by pre-incubation with
a caspase-3 and a caspase-8 inhibitor, indicating an external pathway-mediated effect (F ). Interestingly, known pro-apoptotic cytokines were
only found in marginal concentrations in the mononuclear cell secretome (G). Blocking pathways associated with apoptosis by neutralizing anti-
bodies had no effect on mononuclear cell secretome-induced histone release (H ).
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Discussion
In this study, we showed for the first time that a systemic, high-
dose application of MNC secretome attenuates EAM. In vitro ana-
lysis revealed an apoptosis-inducing effect of MNC secretome on
CD4+ T cells. This observation was reversible by blocking the ex-
ternal apoptosis pathway.
Myocarditis is one of the leading causes for iDCM. The patho-
physiology underlying the disease is still not completely under-
stood. Nevertheless, autoimmunity is considered a key factor
promoting ongoing inflammation, fibrosis, and pathological
remodelling. Accordingly, specific subgroups of affected patients
may take advantage of immunosuppressive treatment. However,
first clinical trials testing immunosuppression for acute myocarditis
failed. In a study by Parrillo et al.24 no advantage of immunosup-
pressive treatment was found. The Myocarditis Treatment Trial,
comparing a placebo group to two immunosuppressive regimens
(prednisolone and azathioprine or prednisolone and cyclosporine)
came up with similar results a few years later.4 Both trails suggest
that immunosuppression is not an option for the treatment of
acute, viral myocarditis and this view was followed in the guide-
lines.25,26 The question of immunosuppression for myocarditis
Figure 3 Continued.
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was readdressed when knowledge on pathophysiological aspects
of myocarditis increased. Whereas in earlier studies patients
were recruited without excluding cases of an acute viral myocardi-
tis, Wojnicz et al.27 treated patients with chronic inflammatory
heart disease and increased HLA expression on heart biopsies,
with either prednisolone and azathioprine or placebo for 3
months. LVEF improved significantly in the immunosuppression
group, even 2 years after treatment. These encouraging results
were confirmed by Frustaci et al.6,28 on patients which fulfilled cri-
teria for inflammatory heart disease but had no evidence of viral
genome in biopsy samples. Future clinical trials testing immunomo-
dulatory or immunosuppressive drug regimens should carefully dis-
tinguish between patients with acute viral myocarditis and chronic
inflammatory heart disease where autoimmunity is the prevailing
cause for ongoing disease after clearance of the virus. Tests meas-
uring autoantibody load might help to better define forms of auto-
immune myocarditis and could be valuable to monitor disease
severity in the future.29
The EAM model was first described by Neu et al.30 The experi-
mental basis of the EAM model is an immunization with a cardiac
specific peptide—MyHC-a. Susceptible mouse strains such as
Balb/c are immunized by a subcutaneously injection of an homolo-
gous a-myosin fragment together with a strong adjuvant.15 The
EAM model is currently considered the best available model mim-
icking autoimmune mechanisms of inflammatory heart disease. It
offers the great advantage to study disease pathogenesis and treat-
ment effects in vivo in the absence of an infective agent.31 However,
despite the advantage in testing new and promising therapeutic
targets, data from animal models should be estimated with
caution and must not uncritically be extrapolated to the human
system.
We have found that treating mice with MNC secretome inhib-
ited the development of an autoimmune myocarditis. This
finding, however, was restricted to an application of the compound
on Day 14, because treatment on Day 0 and Day 7 had no impact
on disease severity. The reason for this might be a time-limited
effect of MNC secretome on CD4+ cell suppression in vivo. In
the EAM model, the injected myosin fragment persists at the de-
position site and the injected MyHC-a/PBS/CFA suspension can
be still found at the time of scarification when opening the inguinal
region. On the other hand the half-life of the MNC secretome is
currently unknown, however, as the effective components are
most likely peptides/proteins a rapid decline in function can be
considered within 24 h. Another explanation for the time-
dependent efficacy of MNC secretome could be distinct immuno-
logical processes at different stages of EAM. During the sensitiza-
tion phase dendritic cell function is crucial. Dendritic cells take
up the injected myosin homologue, process it, and present it to
naı¨ve CD4+ T cells. Interestingly, MNC secretome had only a
marginal impact on DC function. Maturation to LPS stimulation
was only minimally impaired and endocytosis was unaltered in
the presence of MNC secretome.
A major limitation of this study is that mice were treated by a
single-dose protocol and the effect was only monitored on Day
21. Data on long-term effects of MNC secretome treatment are
still missing. In addition, myocarditis is a chronic disease in the clin-
ical scenario, therefore, repeated treatment for a longer time
period is necessary. We plan to address these two questions in
a future study.
Stem cells have been shown to possess—besides their regenera-
tive capacity—considerable immunomodulatory features, e.g. they
can effectively reduce lymphocyte proliferation in vitro.32 It has
been suggested that these anti-proliferative effects are mediated,
at least partly, via paracrine mechanisms.10,33 The idea of using
‘conditioned’ medium from stem cell cultures instead of stem
cells has recently developed mainly supported by research in the
field of regenerative medicine. Several groups have so far reported
encouraging results of using the secretome of mesenchymal or
bone marrow-derived stem cells in treating myocardial infarc-
tion.7,8,34,35 We have recently expanded the concept of regenera-
tory, stem cell-derived paracrine factors, by showing that the
secretome of PBMC also mediates myocyte protection following
myocardial ischaemia.11– 13 Our findings were corroborated by
the work of Wollert and colleagues36 showing in a detailed analysis
that the secretome derived from stem cells only slightly differs
from the secretome from peripheral blood leucocytes. A major
advantage of using paracrine factors from PBMC instead of stem
cells is that they are easily accessible. Our protocol of dialysis
and lyophilization was developed for an off-the shelf scenario for
future clinical applications. For the dialysis step, a cut-off of
3.5 kD was used to avoid a loss of proteins. Neither dialysis nor
lyophilization had an impact on observed effects (unpublished
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 The CD41 and CD81 cell counts in whole-blood samples obtained 12 and 36 h after mononuclear cell
secretome treatment (n5 4–5)
CD41 (%) CD81 (%) CD4/CD8 ratio CD41/7-AAD pos
12 h
Medium 19.9+1.3 10.8+1.9 2.1+0.3 8.1+0.7
MNC secretome 13.3+1.0 9.3+2.0 1.7+0.4 8.8+2.8
36 h
Medium 23.9+1.6 7.4+1.1 2.9+0.2 5.4+0.5
MNC secretome 19.1+2.4 9.3+0.5 2.0+0.1 10.6+1.1
The CD4+/CD8+ cell ratio was reduced in treated animals when compared with controls. Additionally, CD4+/7-AAD positive cells were found more frequently.
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data). In the clinical setting, MNC secretome could be produced in
analogy to other ‘biologicals’ (e.g. i.v. immunoglobulins) from blood
donations of healthy volunteers. However, strict regulatory prere-
quisites (e.g. virus inactivation, potency assays, and mandated GMP
facilities) have to be met in order to reach human clinical trials.
The main mechanistic finding of this work is the capacity of
MNC secretome to induce apoptosis of CD4+ T cells in vitro
and in vivo. We have thoroughly evaluated this observation in
primary CD4+ T cell cultures, a human JURKAT, and a mouse
CD4+ T cell lymphoma cell line. Although the observed effect
might not be limited to T-helper cells, suppressing the CD4+
cell function is substantial in regard to treating myocarditis. Previ-
ous work has shown that treatment with anti-CD4 monoclonal
antibody significantly improved cardiac functional parameters in a
rat myocarditis model. In addition, lymphocytes obtained from
treated animals showed no proliferative response after in vitro
stimulation with a myosin fragment.18,20 In a tedious work by Vala-
perti et al.,16 the importance of CD4+ cell function in the EAM
model was addressed by showing that treatment with CD11b+
monocytes, suppressed the CD4+ dependent, MyHC-a-specific
autoimmune response. These findings are supported by the clinical
observation that T cell depletion is a possible rescue therapy for
fulminant autoimmune myocarditis.37,38
Autoantibody formation is a well-described feature in the patho-
genesis of myocarditis. Antibodies against a wide range of recep-
tors, mitochondrial, and contractile proteins have been found
both in human and in animal models.39 Myosin-specific antibodies
are detectable in 46% of sera from patients suffering from dilated
cardiomyopathy in western blot analysis.40 In contrast to this clin-
ical observation, autoantibody formation is not directly involved in
the development of myocardial infiltrates in the EAM model, since
B-cell deficient mice still develop a myocarditis.22 However, levels
of anti-myosin antibodies can be considered a surrogate marker to
monitor disease severity in the EAM model. In our study,
decreased circulating anti-myosin IgG1 and IgM together with
reduced levels of IL-1b, IL-6, and TGF-b underline the therapeutic
effect of MNC secretome.
One limitation of this study is that the MNC secretome by def-
inition comprises of a myriad of proteins.36 Currently, although a
detailed mapping of the protein content of MNC secretome has
been performed, we have only limited knowledge regarding the
factors mediating observed effects. Unfortunately, this is an un-
solved problem for most of the work done in the field of secre-
tome research. In some studies, potential target proteins were
inactivated by blocking antibodies, however, effects were uniformly
at most partially reversible.12,35,41 In this present study, we tried to
correlate the apoptosis-inducing capacity of MNC secretome to
known apoptosis-relevant factors. TNF-a, sCD40L, and sFAS
were only marginally present in MNC secretome, sFASL was not
detectable as determined by the ELISA technique. In addition,
blocking different pathways associated with programmed cell
death by neutralizing antibodies did not affect histone release in
CD4+ cell cultures. Interestingly, non-protein mediated mechan-
isms of conditioned medium were put up for discussion recently.
Timmers and collegues42 could show that exosomes consisting
of cholesterol, sphingomyelin, and phosphatidylcholine-mediated
cardioprotective effect.
To the best of our knowledge, this is the first study evaluating
immunosuppressive features of a high-dose application of MNC
secretome in the murine EAM model. Further studies are war-
ranted to perpetuate the concept of using MNC secretome for
the treatment of myocarditis.
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Supplementary material is available at European Heart Journal
online.
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